Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis.

× No keyword cloud information.

9 in total

1. [Intolerance of specific immunotherapy with Hymenoptera venom: jumping the hurdle with omalizumab].

Authors: D Wieczorek; A Kapp; B Wedi
Journal: Hautarzt Date: 2014-09 Impact factor: 0.751

2. Honey bee venom re-challenge during specific immunotherapy: prolonged cardio-pulmonary resuscitation allowed survival in a case of near fatal anaphylaxis.

Authors: Sara Micaletto; Kurt Ruetzler; Martin Bruesch; Peter Schmid-Grendelmeier
Journal: Allergy Asthma Clin Immunol Date: 2022-06-02 Impact factor: 3.373

3. Omalizumab ensures compatibility to bee venom immunotherapy (VIT) after VIT-induced anaphylaxis in a patient with systemic mastocytosis.

Authors: Askin Gülsen; Franziska Ruëff; Uta Jappe
Journal: Allergol Select Date: 2021-03-11

4. The bee sting that was not: an unusual case of hymenoptera anaphylaxis averted in a patient treated with omalizumab for asthma.

Authors: Evelyn M Slaughter; Nathan Boyer; Steven Bennett
Journal: Case Rep Med Date: 2014-08-12

Review 5. Advances in the understanding and clinical management of mastocytosis and clonal mast cell activation syndromes.

Authors: David González-de-Olano; Almudena Matito; Alberto Orfao; Luis Escribano
Journal: F1000Res Date: 2016-11-14

6. Combination of omalizumab and bee venom immunotherapy: does it work?

Authors: İnsu Yılmaz; Sakine Nazik Bahçecioğlu; Murat Türk
Journal: Asia Pac Allergy Date: 2018-01-09

Review 7. Use of biologics in allergen immunotherapy.

Authors: Wolfgang Pfützner; Mathias Schuppe
Journal: Allergol Select Date: 2021-02-19

8. Omalizumab, an anti-immunoglobulin E antibody: state of the art.

Authors: Cristoforo Incorvaia; Marina Mauro; Marina Russello; Chiara Formigoni; Gian Galeazzo Riario-Sforza; Erminia Ridolo
Journal: Drug Des Devel Ther Date: 2014-02-07 Impact factor: 4.162

9. Successful prevention of recurrent anaphylactic events with anti-immunoglobulin E therapy.

Authors: Jaechun Lee
Journal: Asia Pac Allergy Date: 2014-04-29

9 in total